Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis

被引:53
作者
Bozzini, Claudia [1 ]
Campostrini, Natascia [1 ]
Trombini, Paola [2 ]
Nemeth, Elizabeta [3 ]
Castagna, Annalisa [1 ]
Tenuti, Ilaria [1 ]
Corrocher, Roberto [1 ]
Camaschella, Clara [4 ]
Ganz, Tomas [3 ]
Olivieri, Oliviero [1 ]
Piperno, Alberto [2 ]
Girelli, Domenico [1 ]
机构
[1] Univ Verona, Dept Clin & Expt Med, Policlin GB Rossi, I-37134 Verona, Italy
[2] Univ Milan, Bicocca S Gerardo Hosp, Dept Clin Med & Prevent, Monza, Italy
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med Pathol, Los Angeles, CA 90095 USA
[4] Univ Vita Salute San Raffaele, Milan, Italy
关键词
hepcidin; hemochromatosis; SELDI-TOF-MS;
D O I
10.1016/j.bcmd.2007.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Insufficient production of hepcidin, the master regulator of iron metabolism, is recognized as the key pathogenetic feature of HFE-related hereditary hemochromatosis (HH). There is a growing interest in measuring the hepcidin levels, which may improve the diagnosis, prognostic evaluation and clinical management of HH. Nevertheless, few investigative tools are available: an immunodot method for urinary hepcidin developed by a single centre (UCLA), not yet ready for large-scale diffusion, and mass spectrometry (MS) based assays, such as surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF-MS). The latter is well suited to small peptides like hepcidin, and can rapidly analyze crude samples with high throughput. This study measured urinary hepcidin levels by SELDI-TOF-MS in a large group of HH patients at diagnosis and during treatment, including both C282Y homozygous and C282Y/H63D compound heterozygotes. Methods: We used a protocol based on PBSIIc mass spectrometer and Normal Phase chips. Urinary samples from 30 control subjects were compared to those obtained from 80 HH patients (57 C282Y homozygotes, 23 C282Y/H63D compound heterozygotes). Eighteen C282Y homozygotes and II C282Y/H63D compound heterozygotes were analyzed at diagnosis, the remainder during maintenance phlebotomy. Results: C282Y homozygotes either at diagnosis, or after phlebotomy had significantly lower urinary hepcidin levels than controls (P<0.05). C282Y/H63D compound heterozygotes had hepcidin levels at diagnosis higher than controls, while the hepcidin/ferritin ratio was significantly decreased (P<0.001) suggesting inadequate hepcidin production. After phlebotomy, mean hepcidin levels in the compound heterozygotes were significantly lower than in controls (P<0.001). Samples from 12 randomly selected control subjects were sent to UCLA for duplicate measurement by the immunodot method, yielding a significant correlation (rho= 0.64; P=0.024). Conclusions: This study supports the use of SELDI-TOF-MS for measuring hepcidin levels in research and clinical applications. Our results in phlebotomized patients suggest that the depletion of iron stores may further exacerbate the HFE-related hepcidin defect. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:347 / 352
页数:6
相关论文
共 27 条
  • [1] EASL International Consensus Conference on Haemochromatosis - Part II. Expert document
    Adams, P
    Brissot, P
    Powell, L
    [J]. JOURNAL OF HEPATOLOGY, 2000, 33 (03) : 487 - 496
  • [2] Hemochromatosis and iron-overload screening in a racially diverse population
    Adams, PC
    Reboussin, DM
    Barton, JC
    McLaren, CE
    Eckfeldt, JH
    McLaren, GD
    Dawkins, FW
    Acton, RT
    Harris, EL
    Gordeuk, VR
    Leiendecker-Foster, C
    Speechley, M
    Snively, BM
    Holup, JL
    Thomson, E
    Sholinsky, P
    Acton, RT
    Barton, JC
    Dixon, D
    Rivers, CA
    Tucker, D
    Ware, JC
    McLaren, CE
    McLaren, GD
    Anton-Culver, H
    Baca, JA
    Bent, TC
    Brunner, LC
    Dao, MM
    Jorgensen, KS
    Kuniyoshi, J
    Le, HD
    Masatsugu, MK
    Meyskens, FL
    Morohashi, D
    Nguyen, HP
    Panagon, SN
    Phung, C
    Raymundo, V
    Ton, T
    Walker, AP
    Wenzel, LB
    Ziogas, A
    Adams, PC
    Bloch, E
    Chakrabarti, S
    Fleischhauer, A
    Harrison, H
    Jia, K
    Larson, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1769 - 1778
  • [3] Decreased liver hepcidin expression in the Hfe knockout mouse
    Ahmad, KA
    Ahmann, JR
    Migas, MC
    Waheed, A
    Britton, RS
    Bacon, BR
    Sly, WS
    Fleming, RE
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2002, 29 (03) : 361 - 366
  • [4] Iron homeostasis
    Andrews, Nancy C.
    Schmidt, Paul J.
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 2007, 69 : 69 - 85
  • [5] Iron storage disease: Facts, fiction and progress
    Beutler, Emest
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2007, 39 (02) : 140 - 147
  • [6] Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis
    Bridle, KR
    Frazer, DM
    Wilkins, SJ
    Dixon, JL
    Purdie, DM
    Crawford, DHG
    Subramaniam, VN
    Powell, LW
    Anderson, GJ
    Ramm, GA
    [J]. LANCET, 2003, 361 (9358) : 669 - 673
  • [7] Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders
    Camaschella, C
    [J]. BLOOD, 2005, 106 (12) : 3710 - 3717
  • [8] Proteomics techniques and their application to hematology
    Cristea, IM
    Gaskell, SJ
    Whetton, AD
    [J]. BLOOD, 2004, 103 (10) : 3624 - 3634
  • [9] The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
    Donovan, A
    Lima, CA
    Pinkus, JL
    Pinkus, GS
    Zon, LI
    Robine, S
    Andrews, NC
    [J]. CELL METABOLISM, 2005, 1 (03) : 191 - 200
  • [10] FINCH CA, 1986, WESTERN J MED, V145, P657